참고문헌
- Bristow RE, Palis BE, Chi DS, et al (2010). The National Cancer Database report on advanced-stage epithelial ovarian cancer: impact of hospital surgical case volume on overall survival and surgical treatment paradigm. Gynecol Oncol, 118, 262-7. https://doi.org/10.1016/j.ygyno.2010.05.025
- Cao R, Wang L, Wang H, et al (2002). Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science, 298, 1039-43. https://doi.org/10.1126/science.1076997
- Danial NN, Korsmeyer SJ (2004). Cell death: critical control points. Cell, 116, 205-19. https://doi.org/10.1016/S0092-8674(04)00046-7
- Davies BR, Worsley SD, Ponder BA (1998). Expression of E-cadherin, alpha-catenin and beta-catenin in normal ovarian surface epithelium and epithelial ovarian cancers. Histopathology, 32, 69-80. https://doi.org/10.1046/j.1365-2559.1998.00341.x
- Glazer RI, Hartman KD, Knode MC, et al (1986). 3-Deazaneplanocin: a new and potent inhibitor of S-adenosylhomocysteine hydrolase and its effects on human promyelocytic leukemia cell line HL-60. Biochem Biophys Res Commun, 135, 688-94. https://doi.org/10.1016/0006-291X(86)90048-3
- Guo J, Cai J, Yu L, et al (2011). EZH2 regulates expression of p57 and contributes to progression of ovarian cancer in vitro and in vivo. Cancer Sci, 102, 530-9. https://doi.org/10.1111/j.1349-7006.2010.01836.x
- Hudson LG, Zeineldin R, Stack MS (2008). Phenotypic plasticity of neoplastic ovarian epithelium: unique cadherin profiles in tumor progression. Clin Exp Metastasis, 25, 643-55. https://doi.org/10.1007/s10585-008-9171-5
- Imai T, Horiuchi A, Shiozawa T, et al (2004). Elevated expression of E-cadherin and alpha-, beta-, and gamma-catenins in metastatic lesions compared with primary epithelial ovarian carcinomas. Hum Pathol, 35, 1469-76. https://doi.org/10.1016/j.humpath.2004.09.014
- Kalushkova A, Fryknas M, Lemaire M, et al (2010). Polycomb target genes are silenced in multiple myeloma. PLoS One, 5, e11483. https://doi.org/10.1371/journal.pone.0011483
- Kikuchi J, Takashina T, Kinoshita I, et al (2012). Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells. Lung Cancer, 78, 138-43. https://doi.org/10.1016/j.lungcan.2012.08.003
- Kuzmichev A, Nishioka K, Erdjument-Bromage H, et al (2002). Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. Genes Dev, 16, 2893-905. https://doi.org/10.1101/gad.1035902
- Landen CN Jr, Birrer MJ, Sood AK (2008). Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol, 26, 995-1005. https://doi.org/10.1200/JCO.2006.07.9970
- Liu S, Wolfe MS, Borchardt RT (1992). Rational approaches to the design of antiviral agents based on S-adenosyl-Lhomocysteine hydrolase as a molecular target. Antiviral Res, 19, 247-65. https://doi.org/10.1016/0166-3542(92)90083-H
- Orrenius S, Zhivotovsky B, Nicotera P (2003). Regulation of cell death: the calcium-apoptosis link. Nat Rev Mol Cell Biol, 4, 552-65. https://doi.org/10.1038/nrm1150
- Rao ZY, Cai MY, Yang GF, et al (2010). EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients. Carcinogenesis, 31, 1576-83. https://doi.org/10.1093/carcin/bgq150
- Rizzo S, Hersey JM, Mellor P, et al (2011). Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Mol Cancer Ther, 10, 325-35. https://doi.org/10.1158/1535-7163.MCT-10-0788
- Sasaki D, Imaizumi Y, Hasegawa H, et al (2011). Overexpression of Enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy. Haematologica, 96, 712-19. https://doi.org/10.3324/haematol.2010.028605
- Tan J, Yang X, Zhuang L, et al (2007). Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev, 21, 1050-63. https://doi.org/10.1101/gad.1524107
피인용 문헌
- Histones and Their Modifications in Ovarian Cancer – Drivers of Disease and Therapeutic Targets vol.4, pp.2234-943X, 2014, https://doi.org/10.3389/fonc.2014.00144
- Epigenetics in ovarian cancer: premise, properties, and perspectives vol.17, pp.1, 2018, https://doi.org/10.1186/s12943-018-0855-4